| Dr Matthew B Harper, MD | |
|
2201 Lexington Ave, Ashland, KY 41101-2843 | |
| (606) 408-4000 | |
| (606) 408-6212 |
| Full Name | Dr Matthew B Harper |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 14 Years |
| Location | 2201 Lexington Ave, Ashland, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568783744 | NPI | - | NPPES |
| 103024617 | Medicaid | PA |
| Facility Name | Location | Facility Type |
|---|---|---|
| King's Daughters' Medical Center | Ashland, KY | Hospital |
| Kings Daughters Medical Center Ohio | Portsmouth, OH | Hospital |
| Three Rivers Medical Center | Louisa, KY | Hospital |
| Southern Ohio Medical Center | Portsmouth, OH | Hospital |
| St Mary's Medical Center | Huntington, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ashland Hospital Corporation | 7719882521 | 147 |
| Ashland Hospital Corporation | 7719882521 | 147 |
News Archive
Sociologic factors such as marital status and living location before hospitalization are key predictors of time to discharge in male veterans after lower extremity amputation, report researchers.
In a laboratory experiment, the scientists from NYU School of Medicine discovered that Staphylococcus aureus, a notorious bacterium that causes toxic shock syndrome and many other types of infections and is the scourge of hospitals nationwide due to its growing antibiotic resistance, could co-opt viral parasites as secret pipelines for transferring toxin genes to vastly different bacterial species.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 10,350,000 shares of its common stock, including 1,350,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offered by the Company. Net proceeds were approximately $53.3 million after deducting underwriting discounts and commissions, and estimated offering expenses. Canaccord Adams acted as sole book-running manager and Needham & Company, LLC acted as co-manager for the offering.
Dr. Marc McKee, of McGill's Faculty of Dentistry and the Department of Anatomy and Cell Biology, is collaborating closely with Enobia Pharma Inc, a Quebec biotech company, to develop innovative treatments for serious genetic bone diseases. McKee's research looks into the reasons why calcium-phosphate mineral fails to crystallize properly to form strong bones and teeth.
In Q3 of 2013, Randox announced that the Food and Drug Administration has approved the company's Acusera Immunoassay Speciality 1 quality control for use in US laboratories.
› Verified 3 days ago
| Entity Name | Ashland Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659328250 PECOS PAC ID: 7719882521 Enrollment ID: O20031204000877 |
News Archive
Sociologic factors such as marital status and living location before hospitalization are key predictors of time to discharge in male veterans after lower extremity amputation, report researchers.
In a laboratory experiment, the scientists from NYU School of Medicine discovered that Staphylococcus aureus, a notorious bacterium that causes toxic shock syndrome and many other types of infections and is the scourge of hospitals nationwide due to its growing antibiotic resistance, could co-opt viral parasites as secret pipelines for transferring toxin genes to vastly different bacterial species.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 10,350,000 shares of its common stock, including 1,350,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offered by the Company. Net proceeds were approximately $53.3 million after deducting underwriting discounts and commissions, and estimated offering expenses. Canaccord Adams acted as sole book-running manager and Needham & Company, LLC acted as co-manager for the offering.
Dr. Marc McKee, of McGill's Faculty of Dentistry and the Department of Anatomy and Cell Biology, is collaborating closely with Enobia Pharma Inc, a Quebec biotech company, to develop innovative treatments for serious genetic bone diseases. McKee's research looks into the reasons why calcium-phosphate mineral fails to crystallize properly to form strong bones and teeth.
In Q3 of 2013, Randox announced that the Food and Drug Administration has approved the company's Acusera Immunoassay Speciality 1 quality control for use in US laboratories.
› Verified 3 days ago
| Entity Name | Ashland Radiology Associates Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285025395 PECOS PAC ID: 7315265766 Enrollment ID: O20150424002022 |
News Archive
Sociologic factors such as marital status and living location before hospitalization are key predictors of time to discharge in male veterans after lower extremity amputation, report researchers.
In a laboratory experiment, the scientists from NYU School of Medicine discovered that Staphylococcus aureus, a notorious bacterium that causes toxic shock syndrome and many other types of infections and is the scourge of hospitals nationwide due to its growing antibiotic resistance, could co-opt viral parasites as secret pipelines for transferring toxin genes to vastly different bacterial species.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 10,350,000 shares of its common stock, including 1,350,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offered by the Company. Net proceeds were approximately $53.3 million after deducting underwriting discounts and commissions, and estimated offering expenses. Canaccord Adams acted as sole book-running manager and Needham & Company, LLC acted as co-manager for the offering.
Dr. Marc McKee, of McGill's Faculty of Dentistry and the Department of Anatomy and Cell Biology, is collaborating closely with Enobia Pharma Inc, a Quebec biotech company, to develop innovative treatments for serious genetic bone diseases. McKee's research looks into the reasons why calcium-phosphate mineral fails to crystallize properly to form strong bones and teeth.
In Q3 of 2013, Randox announced that the Food and Drug Administration has approved the company's Acusera Immunoassay Speciality 1 quality control for use in US laboratories.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew B Harper, MD Po Box 2379, Ashland, KY 41105-2379 Ph: (606) 408-6200 | Dr Matthew B Harper, MD 2201 Lexington Ave, Ashland, KY 41101-2843 Ph: (606) 408-4000 |
News Archive
Sociologic factors such as marital status and living location before hospitalization are key predictors of time to discharge in male veterans after lower extremity amputation, report researchers.
In a laboratory experiment, the scientists from NYU School of Medicine discovered that Staphylococcus aureus, a notorious bacterium that causes toxic shock syndrome and many other types of infections and is the scourge of hospitals nationwide due to its growing antibiotic resistance, could co-opt viral parasites as secret pipelines for transferring toxin genes to vastly different bacterial species.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 10,350,000 shares of its common stock, including 1,350,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offered by the Company. Net proceeds were approximately $53.3 million after deducting underwriting discounts and commissions, and estimated offering expenses. Canaccord Adams acted as sole book-running manager and Needham & Company, LLC acted as co-manager for the offering.
Dr. Marc McKee, of McGill's Faculty of Dentistry and the Department of Anatomy and Cell Biology, is collaborating closely with Enobia Pharma Inc, a Quebec biotech company, to develop innovative treatments for serious genetic bone diseases. McKee's research looks into the reasons why calcium-phosphate mineral fails to crystallize properly to form strong bones and teeth.
In Q3 of 2013, Randox announced that the Food and Drug Administration has approved the company's Acusera Immunoassay Speciality 1 quality control for use in US laboratories.
› Verified 3 days ago
Eugene R Degiorgio, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 1000 Saint Christopher Dr, Ashland, KY 41101 Phone: 606-833-2273 | |
Garrick Todd Sherman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 Fax: 606-408-6212 | |
Anshu K Jain, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 122 Saint Christopher Dr, Ashland, KY 41101 Phone: 606-836-0202 | |
Mayola W Boykin, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 | |
Robert Ray Penkava, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 | |
Dr. Dhirenkumar Desai, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 | |
Dr. Pho M. Nguyen, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 613 23rd St Ste 520, Ashland, KY 41101 Phone: 606-393-0190 Fax: 606-393-5169 |